Not a real patient.

Home

Bladder Cancer Overview

Bladder Cancer Prevalence

Diagnosing Bladder Cancer

Types of Bladder Cancer

Unmet Needs in NMIBC

BCG Treatment

Understaging

Inadequate Treatment

Recurrence and Progression

Quality of Life Outcomes

Resources

UNCOVER THE UNMET NEEDS IN HIGH-RISK NMIBC1

Is single-agent BCG delivering the results you expect?

Despite positive response rates with single-agent BCG, many patients with high-risk non–muscle-invasive bladder cancer still experience recurrence, progression, and/or radical cystectomy.1-3

Not a real patient.

BCG=bacillus Calmette-Guérin; NMIBC=non–muscle-invasive bladder cancer.

References: 1. Shore ND, Redorta JP, Robert G, et al. Non-muscle-invasive bladder cancer: an overview of potential new treatment options. Urol Oncol . 2021;39(10):642-663. 2. Holzbeierlein J, Bixler BR, Buckley DI, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline: 2024 amendment. J Urol. 2024. Published online ahead of print January 24, 2024. doi:10.1097JU.0000000000003846 3. Gontero P, Comperat E, Dominguez Escrig JL, et al. EAU guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS). Presented at the EAU Annual Congress Milan. Milan, Italy; March 10-13, 2023.

© 2024 Pfizer Inc. All rights reserved. 
March 2024

This site is intended only for U.S. healthcare professionals. The information provided is for educational purposes only. 

PP-SSN-USA-0012